Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases
Objectives: We aim to report the efficacy and safety of rituximab (RTX) in patients diagnosed with juvenile systemic lupus erythematosus (JSLE) or juvenile idiopathic arthritis (JIA) refractory to conventional treatment. Methods: A retrospective review was made of all medical records of patients wi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Portuguesa de Reumatologia
2016-01-01
|
| Series: | Acta Reumatológica Portuguesa |
| Subjects: | |
| Online Access: | http://www.actareumatologica.com/files/article/1099_anti_cd20_rituximab_therapy_in_refractory_pediatric_rheumatic_diseases_file.pdf |